Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...
news.stv50m
Calls for adoption of action plan on disease affecting one in 10 Scots
A group of clinicians and patients has called on the government at Holyrood to adopt a “Scotland-wide focus” on chronic ...
Investing5m
Commerzbank Q3 beats on revenue, cuts costs but faces rising credit challenges
Commerzbank AG (ETR: CBKG) on Wednesday reported revenues that surpassed consensus estimates by about €55 million, due to ...
manilatimes12m
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
manilatimes32m
ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...